Biodeal Pharmaceuticals just changed its game. The company has bought Biological E’s sterile manufacturing plant in Paonta Sahib, Himachal Pradesh. The deal is worth more than Rs 400 crore. Biodeal is now in the thick of regulated-market injectables.
Before this acquisition, Biodeal operated two WHO-GMP certified facilities and focused on nasal drug delivery systems, specialty formulations, and complex generics.
This deal follows Biodeal’s Rs 385 crore capital raise from RBM Capitalworks. That money was set aside for breaking into regulated markets. Biodeal, based in Noida, Uttar Pradesh, has focused on nasal drug delivery, specialty formulations, and complex generics. It ran two WHO-GMP certified plants. The Paonta Sahib site is a big step up. It changes Biodeal’s reach and its regulatory goals.
Anurag Kumar, Chairman and MD of Biodeal Pharmaceuticals, put it plainly. “Paonta Sahib gives us a regulated-market manufacturing base with credentials and capabilities that normally take years to build. It changes the category of company s and puts us in a strong position to continue building a durable, high-value regulated-market business.” For Biological E, the Hyderabad-based vaccine maker, selling the plant frees up cash for new vaccine R&D and clinical work.
Biodeal Chairman and MD Anurag Kumar emphasized that the Paonta Sahib asset provides a regulated-market manufacturing base with capabilities that would normally take years to build, fundamentally changing the category of company Biodeal competes in.
Biodeal is no longer a niche player. The company is putting over Rs 400 crore on the line and aiming for global regulatory standards. That’s a clear signal. Biodeal wants to take on the big names in injectables. The challenge is clear. Can Biodeal turn this new capacity into market share and regulatory wins? The logic is simple. In contract manufacturing, scale and compliance are just the starting point. Biodeal’s move is bold. If the company stays focused, it could change its place in the regulated-market field.
A PTI report confirms the total spend, including Biodeal’s planned upgrades, is over Rs 400 crore. Mahima Datla, Managing Director of Biological E, called the sale a natural next step. She said Biodeal is well placed to build on what the facility already offers.
